Center for Disease Dynamics, Economics & Policy

Meeting Agenda

Issue Brief

Background Readings

AMFm-related Readings

ICF International and the London School of Hygiene and Tropical Medicine. Independent Evaluation of Phase 1 of the Affordable Medicines Facility - malaria (AMFm). Multi-Country Independent Evaluation Report: Preliminary Report of July 18, 2012.

Expert Advisory Group on the Affordable Medicines Facility-malaria (AMFm). Review of the AMFm Phase 1 Independent Evaluation Preliminary Report. 22 June 2012, Geneva.

Arrow KJ, Panosian, CB, Gelband H. Saving Lives, Buying Time Washington, D.C.: National Academies Press. 2004. (click here for full report)

Bloom BR, Gelband H and Laxminarayan R.  Consultative Forum on AMFm—The Affordable Medicines Facility-malaria. Washington, D.C.: Resources For The Future. 2008.

Laxminarayan R and Gelband H. A Global Subsidy: Key To Affordable Drugs For Malaria? Health Affairs (28) 4 July 2009 | pg. 949-961.

The Global Fund to Fight AIDS, Tuberculosis and Malaria and the World Health Organization. Meeting Report: Consultation on the Economics and Financing of Universal Access to Parasitological Confirmation of Malaria. May 31-June 1 2010. (Appendix 1, Appendix 2)

CDDEP Febrile Illness Consultation Reports

CDDEP. Economics and Financing of Febrile Illness RDTs: Report of Consultation 1. 20 October 2011, Seattle. CDDEP.

CDDEP. Economics and Financing of Febrile Illness RDTs: Report of Consultation 2. 23–24 February 2012, Washington, D.C.

Joint Institute of Medicine/Center for Disease Dynamics, Economics & Policy Meeting

At the end of 2012, AMFm completes a pilot phase—phase 1—in seven countries: Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania and Uganda. The board of the Global Fund to Fight AIDS, TB and Malaria takes up AMFm’s future at a meeting in November, with input from the independent evaluation that they commissioned, which was carried out by ICF International and the London School of Hygiene and Tropical Medicine. At the same time, a working group established by the boards of the Global Fund and the Roll Back Malaria Partnership is engaged in analyses to inform the discussion of subsidized artemisinin-combination therapies (ACTs) and the expanded use of rapid diagnostic tests (RDTs) for malaria. With declines in malaria prevalence in some countries and the expanded availability of diagnostics to easily distinguish malaria from other febrile illnesses comes the imperative to align fever management with the new realities.

This meeting connects these issues: 17 September will be devoted to AMFm and future scenarios, and 18 September to the developing febrile illness management paradigm. The principal investigators of the AMFm independent evaluation, the analysts working on the transition path from AMFm Phase 1, members of the Global Fund and Roll Back Malaria advisory committee, and many experts in febrile illnesses—including malaria and pneumonia—will present their work and views at this meeting, before Global Fund board decisions are taken in November.